TP53 aberrations in chronic lymphocytic leukemia

Advances in Experimental Medicine and Biology

Volumn 792, Issue , 2013, Pages 109-131

  Trbusek, Martin ^a   Malcikova, Jitka ^a  

^a CENTRAL EUROPEAN INSTITUTE OF TECHNOLOGY   (Czech Republic)

Author keywords

Alemtuzumab; Apoptosis; ATM; Chemo refractoriness; Deletion 17p; Prognosis; Relapse; TP53 p53 mutation

Indexed keywords

ALEMTUZUMAB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN MDM2; PROTEIN P53; RITUXIMAB;

ARTICLE; AUTOPHAGY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CARCINOGENESIS; CELL AGING; CELL CYCLE ARREST; CELL FUNCTION; CHRONIC MYELOID LEUKEMIA; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DNA REPAIR; GENE FUNCTION; GENE MUTATION; GENE SEQUENCE; GENE TARGETING; GENETIC DISORDER; GENETIC SCREENING; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; MDM2 GENE; MICROARRAY ANALYSIS; MISSENSE MUTATION; MOLECULAR EVOLUTION; MUTAGENESIS; MUTIDRUG RESISTANCE GENE 1; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; TUMOR SUPPRESSOR GENE;

EID: 84934442378     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-8051-8_5     Document Type: Article

References (149)

1. Lane DP, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells. Nature. 1979;278:261-3.
2. Linzer DI, Levine AJ. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell. 1979;17:43-52.
3. Soussi T. The history of p53. A perfect example of the drawbacks of scientific paradigms. EMBO Rep. 2010;11:822-6.
4. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell. 1989;57:1083-93.
5. Eliyahu D, Michalovitz D, Eliyahu S, et al. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci U S A. 1989;86:8763-7.
6. Lane D. Cancer. p53, guardian of the genome. Nature. 1992;358:15-6.
7. Kenzelmann Broz D, Attardi LD. In vivo analysis of p53 tumor suppressor function using genetically engineered mouse models. Carcinogenesis. 2010;31:1311-8.
8. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250:1233-8.
9. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28:622-9.
10. Bartkova J, Rezaei N, Liontos M, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature. 2006;444:633-7.
11. Bartek J, Bartkova J, Lukas J. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene. 2007;26:7773-9.
12. Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;434:864-70.
13. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010;2:a001008.
14. Scheffner M, Werness BA, Huibregtse JM, et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990;63:1129-36.
15. Mestre-Escorihuela C, Rubio-Moscardo F, Richter JA, et al. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood. 2007;109:271-80.
16. Robles A, Harris C. Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb Perspect Biol. 2010;2:a001016.
17. Khoury MP, Bourdon JC. p53 isoforms: an intracellular microprocessor? Genes Cancer. 2011;2:453-65.
18. Flaman JM, Waridel F, Estreicher A, et al. The human tumour suppressor gene p53 is alternatively spliced in normal cells. Oncogene. 1996;12:813-8.
19. Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009;9:95-107.
20. Sturm I, Bosanquet AG, Hummel M, et al. In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis. BMC Cancer. 2005;5:105.
21. Kochethu G, Delgado J, Pepper C, et al. Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia. Leuk Res. 2006;30:1113-8.
22. Majid A, Richards T, Dusanjh P, et al. TP53 codon 72 polymorphism in patients with chronic lymphocytic leukaemia: identification of a subgroup with mutated IGHV genes and poor clinical outcome. Br J Haematol. 2011;153:533-5.
23. Lavin MF, Gueven N. The complexity of p53 stabilization and activation. Cell Death Differ. 2006;13:941-50.
24. Banin S, Moyal L, Shieh S, et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science. 1998;281:1674-7.
25. Canman CE, Lim DS, Cimprich KA, et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science. 1998;281:1677-9.
26. Pomerantz J, Schreiber-Agus N, Lie'geois N, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell. 1998;92: 713-23.
27. el-Deiry WS, Kern SE, Pietenpol JA, et al. Definition of a consensus binding site for p53. Nat Genet. 1992;1:45-9.
28. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;137:413-31.
29. Burns TF, El-Deiry WS. Microarray analysis of p53 target gene expression patterns in the spleen and thymus in response to ionizing radiation. Cancer Biol Ther. 2003;2:431-43.
30. Amundson SA, Do KT, Vinikoor LC, et al. Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen. Cancer Res. 2008;68:415-24.
31. Zenz T, Häbe S, Denzel T, et al. Detailed analysis of p53 pathway defects in fludarabinerefractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood. 2009;114:2589-97.
32. Mraz M, Malinova K, Kotaskova J, et al. miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia. 2009;23:1159-63.
33. Suzuki H, Yamagata K, Sugimoto K, et al. Modulation of microRNA processing by p53. Nature. 2009;460:529-33.
34. Lane DP, Goh AM. How p53 wields the scales of fate: arrest or death? Transcription. 2012;3.
35. Speidel D. Transcription-independent p53 apoptosis: an alternative route to death. Trends Cell Biol. 2010;20:14-24.
36. Steele AJ, Prentice AG, Hoffbrand AV, et al. p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism. Blood. 2008;112:3827-34.
37. Maiuri MC, Galluzzi L, Morselli E, et al. Autophagy regulation by p53. Curr Opin Cell Biol. 2010;22:181-5.
38. Mahoney E, Lucas DM, Gupta SV, et al. ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. Blood. 2012;120:1262-73.
39. Amrein L, Soulieres D, Johnston JB, et al. p53 and autophagy contribute to dasatinib resistance in primary CLL lymphocytes. Leuk Res. 2011;35:99-102.
40. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356:215-21.
41. Aramayo R, Sherman MB, Brownless K, et al. Quaternary structure of the specific p53-DNA complex reveals the mechanism of p53 mutant dominance. Nucleic Acids Res. 2011;39:8960-71.
42. Malcikova J, Smardova J, Rocnova L, et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. Blood. 2009;114:5307-14.
43. Dittmer D, Pati S, Zambetti G, et al. Gain of function mutations in p53. Nat Genet. 1993;4:42-6.
44. Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol. 2010;2:a001107.
45. Chin KV, Ueda K, Pastan I, et al. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science. 1992;255:459-62.
46. Solomon H, Madar S, Rotter V. Mutant p53 gain of function is interwoven into the hallmarks of cancer. J Pathol. 2011;225:475-8.
47. Solomon H, Buganim Y, Kogan-Sakin I, et al. Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature. J Cell Sci. 2012;125:3144-52.
48. Song H, Hollstein M, Xu Y. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol. 2007;9:573-80.
49. Gualberto A, Aldape K, Kozakiewicz K, et al. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc Natl Acad Sci U S A. 1998;95:5166-71.
50. Trbusek M, Smardova J, Malcikova J, et al. Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia. J Clin Oncol. 2011;29:2703-8.
51. Berns A. Cancer biology: can less be more for p53? Nature. 2006;443:153-4.
52. Kato S, Han SY, Liu W, et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A. 2003;100:8424-9.
53. Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2010;2010:481-8.
54. Gaidano G, Ballerini P, Gong JZ, et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 1991;88:5413-7.
55. Fenaux P, Preudhomme C, Lai JL, et al. Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis. Leukemia. 1992;6:246-50.
56. el Rouby S, Thomas A, Costin D, et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood. 1993;82:3452-9.
57. Juliusson G, Oscier DG, Fitchett M, et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med. 1990;323:720-4.
58. Pittman S, Catovsky D. Prognostic significance of chromosome abnormalities in chronic lymphocytic leukaemia. Br J Haematol. 1984;58:649-60.
59. Dohner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood. 1995;85: 1580-9.
60. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910-6.
61. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446-56.
62. Oscier D, Wade R, Orchard JA, et al. Prognostic factors in the UK LRF CLL4 trial. Blood. 2006;108:299.
63. Baker SJ, Preisinger AC, Jessup JM, et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res. 1990;50:7717-22.
64. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989;342:705-8.
65. Zenz T, Krober A, Scherer K, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood. 2008;112:3322-9.
66. Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010;28:4473-9.
67. Dicker F, Herholz H, Schnittger S, et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia. 2009;23:117-24.
68. Rossi D, Cerri M, Deambrogi C, et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res. 2009;15:995-1004.
69. Gonzalez D, Martinez P, Wade R, et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol. 2011;29:2223-9.
70. Pospisilova S, Gonzalez D, Malcikova J, et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia. 2012;26:1458-61.
71. Tam C, Shanafelt T, Wierda W, et al. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood. 2009;114:957-64.
72. Best OG, Gardiner AC, Davis ZA, et al. A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease. Leukemia. 2009;23:212-4.
73. Krober A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100:1410-6.
74. Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood. 2002;100:1177-84.
75. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007;370:230-9.
76. Grever MR, Lucas DM, Dewald GW, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol. 2007;25:799-804.
77. Bosch F, Ferrer A, Villamor N, et al. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clin Cancer Res. 2008;14:155-61.
78. Stilgenbauer S, Kröber A, Busch R, et al. 17p deletion predicts for inferior overall survival after fludarabine-based first line therapy in chronic lymphocytic leukemia: first analysis of genetics in the CLL4 trial of the GCLLSG. Blood. 2005;106:715a.
79. Byrd JC, Gribben JG, Peterson BL, et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol. 2006;24:437-43.
80. Bosch F, Abrisqueta P, Villamor N, et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol. 2009;27:4578-84.
81. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, openlabel, phase 3 trial. Lancet. 2010;376:1164-74.
82. Saddler C, Ouillette P, Kujawski L, et al. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood. 2008;111:1584-93.
83. Dicker F, Herholz H, Schnittger S, et al. Screening for TP53 mutations identifies chronic lymphocytic leukemia patients with rapid disease progression. Blood. 2007;110:490.
84. Zenz T, Hoth P, Busch R, et al. TP53 mutations and outcome after fludarabine and cyclophosphamide (FC) or FC plus rituximab (FCR) in the CLL8 Trial of the GCLLSG. Blood. 2009;114:1267a.
85. Newcomb EW, el Rouby S, Thomas A. A unique spectrum of p53 mutations in B-cell chronic lymphocytic leukemia distinct from that of other lymphoid malignancies. Mol Carcinog. 1995;14:227-32.
86. Zenz T, Vollmer D, TrbusekM, et al. TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia. 2010;24:2072-9.
87. Rodin SN, Rodin AS. Strand asymmetry of CpG transitions as indicator of G1 phasedependent origin of multiple tumorigenic p53 mutations in stem cells. Proc Natl Acad Sci U S A. 1998;95:11927-32.
88. Olivier M, Langerod A, Carrieri P, et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res. 2006;12:1157-67.
89. Young KH, Leroy K, Moller MB, et al. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood. 2008;112:3088-98.
90. Peltonen JK, Vähäkangas KH, Helppi HM, et al. Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival study. Head Neck Oncol. 2011;3:20.
91. Lindenbergh-van der Plas M, Brakenhoff RH, Kuik DJ, et al. Prognostic significance of truncating TP53 mutations in head and neck squamous cell carcinoma. Clin Cancer Res. 2011;17:3733-41.
92. Xu-Monette ZY, Wu L, Visco C, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: a report from an International DLBCL Rituximab-CHOP Consortium Program study. Blood. 2012;120: 3986-96.
93. Dicker F, Kater AP, Prada CE, et al. CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53. Blood. 2006;108: 3450-7.
94. Wierda WG, Castro JE, Aguillon R, et al. A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154. Leukemia. 2010;24: 1893-900.
95. Alonso R, Lo'pez-Guerra M, Upshaw R, et al. Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM. Blood. 2009;114:1563-75.
96. Zainuddin N, Murray F, Kanduri M, et al. TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia. Leuk Res. 2011;35:272-4.
97. Rossi D, Spina V, Deambrogi C, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood. 2011;117:3391-401.
98. Lens D, Dyer MJ, Garcia-Marco JM, et al. p53 abnormalities in CLL are associated with excess of prolymphocytes and poor prognosis. Br J Haematol. 1997;99:848-57.
99. Shanafelt TD, Witzig TE, Fink SR, et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol. 2006;24:4634-41.
100. Stilgenbauer S, Sander S, Bullinger L, et al. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica. 2007;92:1242-5.
101. Trbusek M, Malcikova J, Mayer J. Selection of new TP53 mutations by therapy in chronic lymphocytic leukemia. Leuk Res. 2011;35:981-2.
102. Sturm I, Bosanquet AG, Hermann S, et al. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ. 2003;10:477-84.
103. Hernandez-Boussard TM, Hainaut P. A specific spectrum of p53 mutations in lung cancer from smokers: review of mutations compiled in the IARC p53 database. Environ Health Perspect. 1998;106:385-91.
104. Hussain SP, Schwank J, Staib F, et al. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene. 2007;26:2166-76.
105. Trbusek M, Stano Kozubik K, Malcikova J, et al. Deep sequencing identifies TP53 mutations before their clonal selection by therapy in chronic lymphocytic leukemia. Haematologica. 2012;97:234.
106. Ouillette P, Fossum S, Parkin B, et al. Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks. Clin Cancer Res. 2010;16:835-47.
107. Ouillette P, Collins R, Shakhan S, et al. Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. Blood. 2011;118:3051-61.
108. Pettitt AR, Sherrington PD, Stewart G, et al. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood. 2001;98:814-22.
109. Carter A, Lin K, Sherrington P, et al. Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukaemia. Br J Haematol. 2004;127:425-8.
110. Johnson G, Sherrington P, Carter A, et al. A novel type of p53 pathway dysfunction in chronic lymphocytic leukemia resulting from two interacting single nucleotide polymorphisms within the p21 gene. Cancer Res. 2009;69:5210-7.
111. Lin K, Adamson J, Johnson GG, et al. Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration. Clin Cancer Res. 2012;18:4191-200.
112. Rossi D, Fangazio M, Rasi S, et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood. 2012;119: 2854-62.
113. Badoux XC, Keating MJ, Wierda WG. What is the best frontline therapy for patients with CLL and 17p deletion? Curr Hematol Malig Rep. 2011;6:36-46.
114. Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004;103:3278-81.
115. Osuji N, Del Giudice I, Matutes E, et al. The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica. 2005;90:1435-6.
116. Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous alemtuzumab in fludarabinerefractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2009;27:3994-4001.
117. Doubek M, Trbus?ek M, Malćková J, et al. Specific p53 mutations do not impact results of alemtuzumab therapy among patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53:1817-9.
118. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as firstline therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007;25:5616-23.
119. Cencini E, Sozzi E, Sicuranza A, et al. A pilot monocentric analysis of efficacy and safety of Fludarabine-Campath combination (Flucam) as first line treatment in elderly patients with chronic lymphocytic leukaemia and Tp53 disfunction. Br J Haematol. 2011;154:271-4.
120. Elter T, Gercheva-Kyuchukova L, Pylylpenko H, et al. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. Lancet Oncol. 2011;12:1204-13.
121. Montillo M, Tedeschi A, Petrizzi VB, et al. An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia. Blood. 2011;118:4079-85.
122. Elter T, James R, Busch R, et al. Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia. Leukemia. 2012;26:2549-2552.
123. Parikh SA, Keating MJ, O'Brien S, et al. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood. 2011;118:2062-8.
124. Thornton PD, Matutes E, Bosanquet AG, et al. High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol. 2003;82:759-65.
125. Pettitt AR, Jackson R, Carruthers S, et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. J Clin Oncol. 2012;30:1647-55.
126. Stilgenbauer S, Cymbalista F, Leblond V, et al. Subcutaneous alemtuzumab combined with oral dexamethasone, followed by alemtuzumab maintenance or allo-SCT in CLL with 17p- or refractory to fludarabine-interim analysis of the CLL2O trial of the GCLLSG and FCGCLL/ MW. Blood. 2010;116:920.
127. Bowen DA, Call TG, Jenkins GD, et al. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma. 2007;48:2412-7.
128. Pileckyte R, Jurgutis M, Valceckiene V, et al. Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia. Leuk Lymphoma. 2011;52:1055-65.
129. Smolej L, Doubek M, Panovská A, et al. Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia. Leuk Res. 2012;36:1278-82.
130. Schetelig J, van Biezen A, Brand R, et al. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol. 2008;26:5094-100.
131. Dreger P, Döhner H, Ritgen M, et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood. 2010;116:2438-47.
132. Furman RR, Andritsos L, Flinn IW, et al. Phase 1 Dose Escalation Study of TRU-016, an anti- CD37 SMIPTM protein in relapsed and refractory CLL. Blood. 2010;116:56.
133. Carballido E, Veliz M, Komrokji R, et al. Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia. Cancer Control. 2012;19:54-67.
134. Capitani N, Baldari CT. The Bcl-2 family as a rational target for the treatment of B-cell chronic lymphocytic leukaemia. Curr Med Chem. 2010;17:801-11.
135. Pe'rez-Perarnau A, Coll-Mulet L, Rubio-Patino C, et al. Analysis of apoptosis regulatory genes altered by histone deacetylase inhibitors in chronic lymphocytic leukemia cells. Epigenetics. 2011;6:1228-35.
136. Lin T, Ruppert A, Johnson A, et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol. 2009;27:6012-8.
137. Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood. 2012;120:1175-84.
138. Lanasa MC, Davis PH, Datto M, et al. Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53:218-24.
139. Nahi H, Selivanova G, Lehmann S, et al. Mutated and non-mutated TP53 as targets in the treatment of leukaemia. Br J Haematol. 2008;141:445-53.
140. Muller P, Hrstka R, Coomber D, et al. Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene. 2008;27:3371-83.
141. Best OG, Mulligan SP. Heat shock protein-90 inhibitor, NVP-AUY922, is effective in combination with fludarabine against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotype. Leuk Lymphoma. 2012;53:2314-20.
142. Silva AL, Romao L. The mammalian nonsense-mediated mRNA decay pathway: to decay or not to decay! Which players make the decision? FEBS Lett. 2009;583:499-505.
143. Flaman JM, Frebourg T, Moreau V, et al. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci U S A. 1995;92:3963-7.
144. Smardova J, Pavlova S, Koukalova H. Determination of optimal conditions for analysis of p53 status in leukemic cells using functional analysis of separated alleles in yeast. Pathol Oncol Res. 2002;8:245-51.
145. Chiaretti S, Tavolaro S, Marinelli M, et al. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling. Genes Chromosomes Cancer. 2011;50:263-74.
146. Mohr J, Helfrich H, Fuge M, et al. DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing. Blood. 2011;117:1622-32.
147. Le Garff-Tavernier M, Blons H, Nguyen-Khac F, et al. Functional assessment of p53 in chronic lymphocytic leukemia. Blood Cancer J. 2011;1:e5.
148. Mous R, Jaspers A, Luijks D, et al. Detection of p53 dysfunction in chronic lymphocytic leukaemia cells through multiplex quantification of p53 target gene induction. Leukemia. 2009;23:1352-5.
149. Best O, Gardiner A, Majid A, et al. A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL. Leukemia. 2008;22: 1456-9.